Cargando…
Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
Interstitial lung diseases (ILDs) that are known as diffuse parenchymal lung diseases (DPLDs) lead to the damage of alveolar epithelium and lung parenchyma, culminating in inflammation and widespread fibrosis. ILDs that account for more than 200 different pathologies can be divided into two groups:...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396471/ https://www.ncbi.nlm.nih.gov/pubmed/34445658 http://dx.doi.org/10.3390/ijms22168952 |
_version_ | 1783744380288368640 |
---|---|
author | Samarelli, Anna Valeria Tonelli, Roberto Marchioni, Alessandro Bruzzi, Giulia Gozzi, Filippo Andrisani, Dario Castaniere, Ivana Manicardi, Linda Moretti, Antonio Tabbì, Luca Cerri, Stefania Beghè, Bianca Dominici, Massimo Clini, Enrico |
author_facet | Samarelli, Anna Valeria Tonelli, Roberto Marchioni, Alessandro Bruzzi, Giulia Gozzi, Filippo Andrisani, Dario Castaniere, Ivana Manicardi, Linda Moretti, Antonio Tabbì, Luca Cerri, Stefania Beghè, Bianca Dominici, Massimo Clini, Enrico |
author_sort | Samarelli, Anna Valeria |
collection | PubMed |
description | Interstitial lung diseases (ILDs) that are known as diffuse parenchymal lung diseases (DPLDs) lead to the damage of alveolar epithelium and lung parenchyma, culminating in inflammation and widespread fibrosis. ILDs that account for more than 200 different pathologies can be divided into two groups: ILDs that have a known cause and those where the cause is unknown, classified as idiopathic interstitial pneumonia (IIP). IIPs include idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP) known also as bronchiolitis obliterans organizing pneumonia (BOOP), acute interstitial pneumonia (AIP), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), and lymphocytic interstitial pneumonia (LIP). In this review, our aim is to describe the pathogenic mechanisms that lead to the onset and progression of the different IIPs, starting from IPF as the most studied, in order to find both the common and standalone molecular and cellular key players among them. Finally, a deeper molecular and cellular characterization of different interstitial lung diseases without a known cause would contribute to giving a more accurate diagnosis to the patients, which would translate to a more effective treatment decision. |
format | Online Article Text |
id | pubmed-8396471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83964712021-08-28 Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players Samarelli, Anna Valeria Tonelli, Roberto Marchioni, Alessandro Bruzzi, Giulia Gozzi, Filippo Andrisani, Dario Castaniere, Ivana Manicardi, Linda Moretti, Antonio Tabbì, Luca Cerri, Stefania Beghè, Bianca Dominici, Massimo Clini, Enrico Int J Mol Sci Review Interstitial lung diseases (ILDs) that are known as diffuse parenchymal lung diseases (DPLDs) lead to the damage of alveolar epithelium and lung parenchyma, culminating in inflammation and widespread fibrosis. ILDs that account for more than 200 different pathologies can be divided into two groups: ILDs that have a known cause and those where the cause is unknown, classified as idiopathic interstitial pneumonia (IIP). IIPs include idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP) known also as bronchiolitis obliterans organizing pneumonia (BOOP), acute interstitial pneumonia (AIP), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), and lymphocytic interstitial pneumonia (LIP). In this review, our aim is to describe the pathogenic mechanisms that lead to the onset and progression of the different IIPs, starting from IPF as the most studied, in order to find both the common and standalone molecular and cellular key players among them. Finally, a deeper molecular and cellular characterization of different interstitial lung diseases without a known cause would contribute to giving a more accurate diagnosis to the patients, which would translate to a more effective treatment decision. MDPI 2021-08-19 /pmc/articles/PMC8396471/ /pubmed/34445658 http://dx.doi.org/10.3390/ijms22168952 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Samarelli, Anna Valeria Tonelli, Roberto Marchioni, Alessandro Bruzzi, Giulia Gozzi, Filippo Andrisani, Dario Castaniere, Ivana Manicardi, Linda Moretti, Antonio Tabbì, Luca Cerri, Stefania Beghè, Bianca Dominici, Massimo Clini, Enrico Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players |
title | Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players |
title_full | Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players |
title_fullStr | Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players |
title_full_unstemmed | Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players |
title_short | Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players |
title_sort | fibrotic idiopathic interstitial lung disease: the molecular and cellular key players |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396471/ https://www.ncbi.nlm.nih.gov/pubmed/34445658 http://dx.doi.org/10.3390/ijms22168952 |
work_keys_str_mv | AT samarelliannavaleria fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT tonelliroberto fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT marchionialessandro fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT bruzzigiulia fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT gozzifilippo fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT andrisanidario fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT castaniereivana fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT manicardilinda fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT morettiantonio fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT tabbiluca fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT cerristefania fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT beghebianca fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT dominicimassimo fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers AT clinienrico fibroticidiopathicinterstitiallungdiseasethemolecularandcellularkeyplayers |